Clinical TrialID 8107

Clinical Study of Ligustrazine in Treating Alcohol Addiction

NCT05942352

Alcohol Abuse|Arteriosclerosis

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
8107
Evidence Id
8107
Core Evidence Id
8107
Source Clinical Trial Id
8105
Herb2 Clinical Trial Id
HBCT008105
Nct Id
NCT05942352
Title
Clinical Study of Ligustrazine in Treating Alcohol Addiction
Status
Recruiting
Phase
Phase 4
Study Result
No
Study Condition
Alcohol Abuse|Arteriosclerosis
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Intervention
DRUG: Ligustrazine by intravenously administration|DRUG: Ligustrazine by mouth|DRUG: Placebo by intravenously administration|DRUG: Placebo by mouth
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Quadruple
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
400
Outcome Measure
Relapse rate, Percentage of participants who relapse by assuming that drinking alcohol on more than 3 days in a month in an unrestricted environment is re-drinking, Four week after treatment
Sponsor Collaborator
Shenzhen Kangning Hospital
Funded By
OTHER
Location
Shenzhen Kangning Hospital, Shenzhen, Guangdong, 518118, China
Other Id
2023-K003-02
Start Date
2023-07-28
Primary Completion Date
2024-07
Completion Date
2024-07
First Posted
2023-07-12
Results First Posted
Last Update Posted
2023-10-16
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05942352
Title Cn
Title En
Clinical Study of Ligustrazine in Treating Alcohol Addiction
Bilingual Status
semi_complete